Informações:
Falhas:
ID
13770
Descrição
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01402089
Link
https://clinicaltrials.gov/show/NCT01402089
Palavras-chave
Versões (1)
- 06/03/2016 06/03/2016 -
Transferido a
6 de março de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non Small-cell Lung Cancer NCT01402089
Eligibility Non Small-cell Lung Cancer NCT01402089
- StudyEvent: Eligibility
Similar models
Eligibility Non Small-cell Lung Cancer NCT01402089
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
renal-cell cancer; gastrointestinal stromal tumor; non small-cell lung cancer; sunitinib; erlotinib
Item
histologically or cytologically confirmed renal-cell cancer or gastrointestinal stromal tumor (for sunitinib) or non small-cell lung cancer (for erlotinib)
boolean
C0007134 (UMLS CUI [1])
C0238198 (UMLS CUI [2])
C0007131 (UMLS CUI [3])
C1176020 (UMLS CUI [4])
C1135135 (UMLS CUI [5])
C0238198 (UMLS CUI [2])
C0007131 (UMLS CUI [3])
C1176020 (UMLS CUI [4])
C1135135 (UMLS CUI [5])
tumor stage
Item
both early or advanced tumor stage
boolean
C1300072 (UMLS CUI [1])
sunitinib; erlotinib
Item
indication for the therapeutic use of either sunitinib or erlotinib
boolean
C1176020 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
C1135135 (UMLS CUI [2])
informed consent
Item
written informed consent and willing to undergo pk-sampling
boolean
C0021430 (UMLS CUI [1])
age
Item
patients > 18 years of age
boolean
C0001779 (UMLS CUI [1])
ecog
Item
ecog performance status or ≤2
boolean
C1520224 (UMLS CUI [1])
laboratory parameters
Item
adequate laboratory parameters:
boolean
C0022885 (UMLS CUI [1])
serum creatinine; serum bilirubin; alt and ast; serum calcium
Item
i. serum creatinine and serum bilirubin ≤ 1.5 x uln ii. serum alt and ast ≤ 2.5 x uln (or ≤ 5 in case of liver metastases) iii. serum calcium ≤ 11,6 mg/dl (2.9 mmol/l)
boolean
C0201976 (UMLS CUI [1])
C0428441 (UMLS CUI [2])
C3831581 (UMLS CUI [3])
C0728876 (UMLS CUI [4])
C0428441 (UMLS CUI [2])
C3831581 (UMLS CUI [3])
C0728876 (UMLS CUI [4])
sunitinib; erlotinib
Item
previous treatment with sunitinib or erlotinib
boolean
C1176020 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
C1135135 (UMLS CUI [2])
hypersensitivity study drugs
Item
known hypersensitivity to trial drug or any compounds of the drug
boolean
C0020517 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
concurrent therapy radiotherapy
Item
concurrent radiotherapy
boolean
C0009429 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,2])
concurrent therapy cancer treatment; bisphosphonates; bevacizumab
Item
concurrent systemic anticancer treatment with the exception of bisphosphonates and bevacizumab in patients with non small-cell lung cancer
boolean
C0009429 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
C0012544 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
C0920425 (UMLS CUI [1,2])
C0012544 (UMLS CUI [2])
C0796392 (UMLS CUI [3])